Ongoing Trial of Abemaciclib and Pembrolizumab in HR+/HER2-Negative Breast Cancer

Significant Ki-67 protein suppression in HR-positive, HER2-negative breast cancer was seen among patients treated with lasofoxifene.

In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.

Providers advised to halt use, monitor patients, and report any complications with BioZorb devices to the FDA.

Matthew Hadfield, DO, discusses his passion for early-stage clinical trials and the need for more research into immunotherapy toxicities during the third episode of Emerging Experts.

Holly Pederson, MD, and Elisha Hughes, MD, discussed the use of a polygenic risk score to identify why Black women incur higher rates of triple-negative breast cancer at younger ages.

DeepHRD predicted homologous recombination deficiency with greater accuracy than FDA-approved standard molecular tests.